Literature DB >> 8327664

Development of apoptosis in irradiated murine tumors as a function of time and dose.

L C Stephens1, N R Hunter, K K Ang, L Milas, R E Meyn.   

Abstract

In a previous paper (Radiat. Res. 127, 308-316, 1991), we reported that a moderately radiosensitive, transplantable murine ovarian carcinoma (OCaI) displayed apoptosis after irradiation whereas a radioresistant hepatocellular carcinoma (HCaI) did not. These initial observations have been followed up in this detailed analysis of the development of apoptosis in these two tumors as a function of time and dose. Histological sections of OCaI and HCaI carcinomas were scored at various times between 0.5 and 24 h after single doses of 2.5 or 25 Gy gamma radiation for the incidence of apoptosis. The percentage of nuclei undergoing apoptosis in untreated tumors was 5% in OCaI and 0.6% in HCaI. The peak in the number of apoptotic bodies occurred in the OCaI tumors 3-5 h after either dose. After 2.5 Gy, the peak incidence was about 20% and after 25 Gy it was about 30%. Irrespective of dose, HCaI tumors had an incidence of apoptosis of less than 3%. Based on the results of this time course, 4 h after irradiation was chosen for the determination of the dose response, over doses ranging from 2.5 to 25 Gy. The dose response for the OCaI tumors reached a plateau at 25-30% apoptotic nuclei after doses of about 7.5 Gy and above. Autoradiographic analysis of histological sections from mice injected with [3H]thymidine showed that some apoptotic bodies in the OCaI tumors arose from cycling cells. These results confirm that the apoptotic mode of cell death may represent an important response in some irradiated tumors.

Entities:  

Mesh:

Year:  1993        PMID: 8327664

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  9 in total

Review 1.  Imaging radiation response in tumor and normal tissue.

Authors:  Marjan Rafat; Rehan Ali; Edward E Graves
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

Review 2.  [Significance of apoptotic processes in radiotherapy. II].

Authors:  M Abend; D van Beuningen
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

3.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death.

Authors:  F G Blankenberg; P D Katsikis; J F Tait; R E Davis; L Naumovski; K Ohtsuki; S Kopiwoda; M J Abrams; M Darkes; R C Robbins; H T Maecker; H W Strauss
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Induction of apoptosis in murine tumors by cyclophosphamide.

Authors:  R E Meyn; L C Stephens; N R Hunter; L Milas
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 5.  Programmed cell death and radioresistance.

Authors:  R E Meyn; L C Stephens; L Milas
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

6.  Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.

Authors:  L Milas; N R Hunter; B Kurdoglu; K A Mason; R E Meyn; L C Stephens; L J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Radiation-induced apoptosis in microvascular endothelial cells.

Authors:  R E Langley; E A Bump; S G Quartuccio; D Medeiros; S J Braunhut
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Bi-Functional Radiotheranostics of 188Re-Liposome-Fcy-hEGF for Radio- and Chemo-Therapy of EGFR-Overexpressing Cancer Cells.

Authors:  Yi-Shu Huang; Wei-Chuan Hsu; Chien-Hong Lin; Sheng-Nan Lo; Chu-Nian Cheng; Ming-Syuan Lin; Te-Wei Lee; Chih-Hsien Chang; Keng-Li Lan
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

9.  Molecular Magnetic Resonance Imaging of Tumor Response to Therapy.

Authors:  Adam J Shuhendler; Deju Ye; Kimberly D Brewer; Magdalena Bazalova-Carter; Kyung-Hyun Lee; Paul Kempen; K Dane Wittrup; Edward E Graves; Brian Rutt; Jianghong Rao
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.